What Amgen's Quarter ended Sep 30, 2026 10-Q says: 3 signals
Amgen filed its latest 10-Q with the SEC on Nov 3, 2026. It discusses bookings decline, compliance burden and pricing pressure.
Get Amgen's live signals in Claude or ChatGPT, or by API
What changed at Amgen this week? Use Autobound signals for amgen.com.- Filed
- Nov 3, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 12
Source: Autobound Signal API · 83 signals tracked for Amgen · updated
10-Q · latest 10
What Amgen's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 3 signals
ENBREL net selling price fell 19% in nine months from IRA Medicare price setting
For the nine months ended September 30, 2026, ENBREL sales were negatively impacted by a 19% decline in net selling price due to U.S.
-19%
ENBREL net selling price decline for nine months ended September 30, 2026
Prolia sales dropped 45% in Q3 2026 driven by 23% lower volume from biosimilars
Global Prolia sales fell 45% in the third quarter of 2026, driven by a 23% volume drop following the launch of multiple biosimilars in the U.S.
-23%
Prolia volume decline for the three months ended September 30, 2026
CMS sets mandatory Medicare price setting for ENBREL in 2026 and Otezla in 2027
CMS selected ENBREL and Otezla for Medicare Part D mandatory price setting effective January 1, 2026, and January 2027, respectively, forcing lower prices.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
ENBREL net selling price drops 22% in Q2 2026 due to Medicare Part D price setting
ENBREL net selling price declined 22% in Q2 2026 and 25% for the six months ended June 30, 2026, driven by mandatory Medicare Part D price setting under the IRA and 340B Program mix.
-22%
net selling price decline for ENBREL
European Commission grants marketing authorization for IMDYLLTRA monotherapy in June 2026
In June 2026, Amgen announced that the European Commission granted marketing authorization for IMDYLLTRA as a monotherapy for extensive-stage small cell lung cancer (ES-SCLC).
CMS sets Medicare Part D prices for ENBREL in 2026 and Otezla in 2027
CMS selected ENBREL and Otezla for mandatory Medicare price setting under IRA provisions effective January 1, 2026 and January 2027, respectively.
Amgen secures $60 million U.S. government order for Nplate in first half 2026
Global Nplate sales for the six months ended June 30, 2026, included a U.S.
$60M
U.S. government order for Nplate
23%
increase in global Nplate sales for six months ended June 30, 2026
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 5 signals
FDA Proposes to Withdraw Approval of TAVNEOS and Alerts on Liver Injury Cases
On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS alleging lack of substantial evidence of effectiveness and untrue statements of material facts, following a March 31, 2026 DSC on serious liver injury cases.
CMS Implements Medicare Part D Mandatory Price Setting for ENBREL and Otezla
Under the IRA, CMS implemented mandatory Medicare Part D price setting for ENBREL effective January 1, 2026, and selected Otezla for price setting beginning in 2027.
-15%
lower net selling price resulting from Medicare Part D price setting under the IRA
ENBREL Net Selling Price Falls 15% Due to Medicare Part D Price Setting
Amgen reported a 15% decline in ENBREL net selling price and a 37% total sales decrease to $320 million for the quarter ended March 31, 2026, driven by Medicare Part D price setting and 340B Program mix.
-15%
net selling price decline for ENBREL
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Amgen earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| New Chief Financial Officer appointed to lead capital allocationThomas J. Dittrich joined Amgen as Chief Financial Officer, marking his first quarterly earnings call with the company in this role. Dittrich outlined key priorities focusing on operational efficiency, disciplined capital allocation, and driving durable long-term growth. New leadership often initiates comprehensive vendor and operational strategy reviews. | |
| Deploying artificial intelligence across drug discovery and manufacturing operationsAmgen is implementing artificial intelligence and data-driven insights across enterprise operations to accelerate speed and operational efficiency. The digital initiative spans early drug discovery, clinical development, manufacturing processes, and global product delivery. This creates engagement opportunities for vendors of enterprise AI, life sciences data platforms, and advanced analytics... | |
| Scaling specialized field operations team for bispecific clinical deliveryAmgen has scaled a dedicated field organization termed the bispecific operations team to support clinical adoption and patient safety monitoring. Originally created for hematology and lung cancer drugs, the team is now expanding to support genitourinary oncology practices with outpatient implementation. This commercial model evolution requires healthcare workflow and patient-monitoring support... | |
| Non-GAAP R&D spending increased 11% year-over-yearResearch and development spending grew 11% year-over-year in the third quarter. The increase in spend was driven by investments in research and the early-stage pipeline, alongside business development activities. | |
| Tepezza revenue dropped 6% due to prior-year inventory buildTEPEZZA generated $526 million in sales during Q3, representing a 6% year-over-year decline attributed to comparisons against a significant customer inventory build in the prior year. Despite international launches across more than 20 countries, domestic inventory normalization created a headwind. This dynamic highlights supply-chain visibility and demand-forecasting software needs. | |
| SG&A expenses decreased 1% through targeted ongoing productivity effortsAmgen reduced non-GAAP SG&A expenses by 1% year-over-year in the third quarter, driven in part by ongoing enterprise productivity efforts and the timing of investments. Operating margins reached 47% non-GAAP in Q3, with full-year margin guidance targeting 45% to 46% of product sales. Operational efficiency remains a top agenda item under the new financial leadership. |
Signal API · MCP
Track Amgen with the Signal API
One POST /v1/companies/enrich call with amgen.com returns Amgen 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Amgen 10-Q
When did Amgen file its latest 10-Q?
What did Amgen disclose in its latest 10-Q?
What did Amgen say on its recent earnings calls?
Where can I read Amgen's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .